Abstracts

Efficacy of Long-Acting Cabotegravir and Rilpivirine for PEP in a Macaque Model of RT SHIV Infection

Background: Current recommendations for post-exposure prophylaxis (PEP) for non-occupational HIV exposures include 28 days of daily oral antiretroviral drugs. However, low adherence, and inadequate regimen completion represents an important challenge. We examined whether a single injection of the combination of long-acting cabotegravir and rilpivirine (CAB LA and RPV LA) could be an effective PEP regimen…

PrEP Following PEP: An Effective HIV Risk-Reduction Strategy

Background: From January 2021, individuals attending a sexual health service in London, UK who receive HIV post-exposure prophylaxis following sexual exposure (PEPSE) are offered quick-start opt-out PrEP with a 1-month supply to take immediately following completion of PEP, PEP2PrEP, a risk reduction strategy for individuals with ongoing risk of HIV acquisition. We present the uptake…

A Matter of Time: Factors Associated With Delayed nPEP Initiation

Background: Nonprofessional Post-Exposure Prophylaxis (nPEP) protects against HIV infection after risk exposure, but a prompt start is essential. According to the Italian guidelines, nPEP should be started within 24 hours after the exposure (preferably in the first 4 hours), but can be prescribed up to 72 hours. Aim of this study is to describe factors…

PrEP Uptake and Persistence Among Incarcerated People in Zambia: Early Results From a Cohort Study

Background: The time during and immediately after incarceration can be high-risk periods for HIV acquisition, particularly in sub-Saharan Africa (SSA). Incarcerated people often have very limited access to effective HIV prevention measures. In 2019, Zambia began offering HIV pre-exposure prophylaxis (PrEP) in correctional facilities. We report early results from one of the first longitudinal studies…

Outcomes of a Community-Clinic Hybrid PrEP Trial in China During COVID Lockdowns, 2021-2023

Background: Data on PrEP uptake, persistence, discontinuation, adverse events, and HIV incidence among Chinese at-risk PrEP users is limited. Methods: We conducted a 12 month PrEP demonstration project in Wuhan and Guangzhou, China, using a community and clinic hybrid delivery model for recruitment, participant engagement, and PrEP delivery. Healthcare providers implemented prescribing, medical consultation, and…